There are few data regarding risk assessment in revascularization for critical limb ischaemia, because few validation studies have been published regarding the established risk scores (Finnvasc and PREVENT III). A new risk model has been developed and validated in the clinical setting by comparing it with other established models. This model is offered to the vascular community to encourage its external validation in other clinical environments in order to advance the objective assessment of surgical risk in these patients.
INTRODUCTION
Critical limb ischaemia (CLI) is the most severe form of peripheral arterial disease in the lower limbs. It affects a subgroup of patients with high vascular risk and a high rate of comorbidity, and it is associated with a high risk of death and/or major amputation of the extremity. 1 The treatment of choice is revascularization when technically possible, but not all patients can benefit from it; many patients are too fragile to withstand the intervention and, in many of them, the risk benefit ratio is unfavourable. Published series show that despite revascularization, the rate of death and major amputation in the short and medium term remains high. 2 Furthermore, it is often difficult to decide which patients will benefit from intervention, as the specific weights of several markers of risk are not clearly established.
Moreover, predictive risk models have emerged in the world of surgery as an objective tool for assessing the risk of intervention beyond traditional clinical judgment, which is not without subjective influences. 3 An example of this is the successful and extensively used Euroscore in cardiac surgery. 4 However, in vascular surgery in general (and critical ischaemia in particular), this is an area that is yet to be developed. So far, four predictive risk models have been published for revascularization for CLI.
The Finnvasc risk scale (derived from the Finnish vascular registry) was developed with the aim of predicting amputation free survival (AFS) over 30 days in patients undergoing conventional infrainguinal revascularization surgery. 5 The PREVENT III risk scale (derived from a clinical trial with the same name) was designed to predict AFS 1 year after autologous infrainguinal bypass. 6 The BASIL risk model was established with the aim of predicting the probability of survival (regardless of the risk of amputation) 2 years after revascularization. 7 Finally, the CRAB risk model was developed to predict mortality and major morbidity at 30 days (regardless of the risk of amputation) in patients undergoing infrainguinal bypass. Table 1 . Descriptive analysis of the results of the intervention in the sample and comparison between "Score development" and "Validation" subsamples (*, p < 0.05). .808 AFS ¼ amputation free survival. Table 2 . Descriptive analysis of pre-operative variables in the complete sample, in the "development" and "validation" groups, and comparison between subgroups (*, p < 0.05). However, although there are studies to validate some of these scales, 9e12 their use in clinical practice is scarce, and there are few reliable data regarding their applicability to different populations other than those on which they were developed.
Total sample
(n ¼ 672) n (%) Score development subsample (n ¼ 561) n (%) Validation subsample (n ¼ 111) n (%)
Objective
The aim of this work was to create a new risk model to predict the risk of death and/or major amputation at 1 year in patients operated on for CLI from the patients in the local area and population, and to compare it with the PREVENT III and Finnvasc scales. The risk model designed was named ERICVA (Escala de Riesgo en Isquemia Crítica de Valladolid, Valladolid Critical Limb Ischaemia Risk Scale).
MATERIALS AND METHODS

Overview
An observational retrospective study of patients operated on for critical ischaemia of the lower limb at Valladolid's University Hospital was designed. The main endpoint in the study was the AFS 1 year after the procedure.
All revascularized patients diagnosed with critical ischaemia (Rutherford stages 4, 5, or 6) between January 1, 2005, and June 30, 2010, were included (conventional or endovascular treatment). Cases of critical ischaemia of nonatherosclerotic aetiology (embolic, traumatic, or vasculitic), patients who did not survive the first 24 hours after intervention, and those cases in which primary major amputation was performed without a previous revascularization procedure, were excluded.
In each patient, age, sex, clinical stage at admission, vascular physical examination, haemodynamic examination (Doppler), vascular risk factors, medication, comorbidity, previous surgery for lower extremity ischaemia, procedure performed, blood tests, 30 day post-operative complications, need for major ipsilateral amputation, and death were registered.
The information was gathered from the intervention sheet filed in the hospital and medical records (paper or digital) of each patient, creating a standardized data sheet for later registration in a computer database. The status of each patient at follow up, in terms of survival and need for major amputation was registered from the clinical history data, by telephone contact and through inquiries in the Civil Registry offices.
Flowchart of the study and statistics
First, a descriptive study of the total sample of patients was performed. Subsequently, the sample was divided into two groups: one for the development of the ERICVA scale (patients operated on between January 1, 2005, and December 31, 2009), and another for the validation of the scale (patients operated on between January 1, 2010, and June 30, 2010). Both groups were compared for any difference with a Student t test for qualitative variables and a chi-square test for quantitative variables (Fig. 1) .
Using the development sample, a univariate Cox regression was conducted to find variables associated with AFS; continuous variables (laboratory parameters) were transformed into discrete variables to perform this analysis (transformation was done using normal laboratory values as cut off points, as shown in Table 3 ).
The variables in the univariate analysis that reached a significance of p < .05 were included in a multivariate Cox regression analysis (backward method) to determine which ones were associated with statistical significance for AFS.
From the variables selected in the Cox regression, the ERICVA risk model was designed, creating an additive score. The value of each item was fixed by multiplying the beta coefficient (Cox regression) by 10 and was rounded to the nearest whole number to facilitate summation. Subsequently, a simplified version of the ERICVA model was designed with the five variables with higher specific weight creating a sum in which each item added one point.
Subsequently, the Finnvasc, PREVENT III, ERICVA, and ERICVA-Simplified scales were applied to both subsamples to assess their predictive ability to detect AFS at 1 year. Receiver operating characteristic curves for each of them were calculated, comparing the area under the curve (AUC) with the DeLong et al. method. 13 All statistical analysis was performed with SPSS 17 (SPSS Inc. Chicago, IL, USA), except AUC comparisons, which were performed with EPIDAT 3.1 (Xunta de Galicia, Spain) software. 
RESULTS
Descriptive analysis
A total of 672 cases with a mean follow up of 778 days were included in the study; 561 cases were included in the subgroup for the development of the ERICVA scale, and the other 111 cases formed the subgroup used for validation and comparison with the other two scales. The characteristics of the sample and comparative analysis of both subgroups (which proved to be very similar) are shown in Tables 1 and 2 . Table 3 shows the results of the univariate Cox regression analysis that was applied to all pre-operative variables regarding major AFS.
Univariate analysis
Multivariate analysis
The variables in the univariate analysis that were associated with death and/or major amputation (p < .05) were included in a multivariate model (Cox regression). In this multivariate analysis, the variables that were statistically significant were cerebrovascular disease, previous contralateral amputation, diabetes mellitus, dialysis, COPD/ asthma, active neoplasm in the previous 5 years, 30% or lower haematocrit, neutrophil/lymphocyte ratio 5 or higher, absence of arterial Doppler signal in the ankle, emergency admission, and Rutherford stage 6 ischaemia ( Table 4) .
Design of ERICVA and simplified ERICVA scales
From the statistically significant variables in the Cox regression, the ERICVA scale was designed so that the betacoefficient of each one was multiplied by 10 and rounded to the nearest whole number, creating an additive scale in which each variable sums a value which is directly proportional to its association with death or major amputation (Table 5) .
To create a simpler version of the scale (which is called ERICVA-Simplified), the five variables with greatest weight were used to create a sum scale in which each item adds 1 point (Table 6 ).
After applying both scales to the development sample, it was found that a higher score correlated with lower AFS. For the ERICVA scale, the distribution of scores was divided in tertiles to create different risk levels (Fig. 2) ; in this way the ERICVA scale was divided into low (0e9 points), medium (10e19 points), and high (20 or more points) risk groups. In a similar way, the simplified ERICVA score was divided into low (0 points), medium (1 point), and high (2 or more points) risk, resulting in a similar KaplaneMeier curve for both scales (Fig. 3 ).
Validation and comparison between different scales in both subsamples
After applying the Finnvasc, PREVENT III, ERICVA, and ERICVA-Simplified scales to the development and validation Table 6 . Simplified ERICVA Scale: the five items with the greatest weight in ERICVA score were selected to create the simplified version.
Simplified
1 point Neutrophil/lymphocyte ratio >5 1 point Rutherford class 6 (major tissue loss) 1 point subsamples, receiver operating characteristic (ROC) curves were constructed to assess the predictive value of each scale for AFS at 1 year (Fig. 4) . The AUC of the ERICVA scale, in its two versions, was significantly higher than the PRE-VENT III and Finnvasc scores; in the validation subsample, there were no significant differences between the AUC of ERICVA (both versions) and PREVENT III scales, but the AUC was significantly higher compared with Finnvasc (Table 7) .
DISCUSSION
The population studied in this work represents a wide spectrum of revascularization techniques for CLI. The findings are in line with most other trials regarding this subject. 1 Moreover, within the homogeneity of the development and validation samples, there were small differences that show the evolution of vascular surgery in recent years, and so more distal endovascular procedures were performed in patients in worse clinical condition. Also, in terms of the variables included in the model, some were included that have not traditionally been associated with worse outcomes in patients with critical ischaemia. The presence of a high neutrophil/lymphocyte ratio reaffirms it once again as a marker of poor prognosis, 14 but revascularization in cancer patients has barely been referenced so far in the literature.
The ERICVA risk model is the first to be developed in Spain, and the second in Europe in the context of revascularization in patients with CLI. In the environment where it has been developed, it allows the objective identification of patients at high risk of death and/or major amputation 1 year after the intervention. Its greatest potential is that it can be helpful in making the decision of whether or not to perform revascularization in a particular patient, and it provides some objectivity when determining surgical risks involved in these procedures. It also allows estimation of the risk profile of patients seen in a given centre, which is useful for making benchmark comparisons. One of the main contributions of this model is the ease of use because of its easier summation. Furthermore, items are easily gathered, since they are drawn from the clinical history, physical examination, vascular examination, and blood tests that are performed routinely on patients treated for CLI. It is very intuitive to use: the higher the score, the higher the rate of death and/or major amputation at 1 year. The ERICVA-Simplified version is a more simple application which maintains the same level of reliability and that can be performed at the patient's bedside.
One of the questions posed by risk models is their predictive capacity away from the local population environment where they have been developed. In this study it was observed that the Finnvasc scale revealed a low predictive ability, while the PREVENT III scale showed a relatively good performance in the development sample. As for the ERICVA model, which was useful locally, its usefulness in other locations has yet to be proven.
Another of the difficulties that risk models face is their validity over time. It is known that over the years, surgical indications change and new techniques emerge, and the clinical profiles of the intervened population are not the same; it is questionable, therefore, whether the validity of the risk model persists after such changes. This is why updating databases and recalibration of the risk scales is fundamental.
There are several characteristics that must be observed when evaluating a predictive model (Table 8) . First is the target variable. In the Finnvasc, PREVENT III, and ERICVA scales, this target variable was AFS, whereas in the CRAB scale it was mortality and major morbidity, and in the BASIL model the target variable was survival at 2 years. It is believed that, unlike the CRAB and BASIL models, it is important to consider the risk of amputation in assessing the outcome of revascularization for CLI. The time when the unfavourable event happens is also important and can be evaluated in the immediate pre-operative period (CRAB scales and Finnvasc), at 1 year (scales Finnvasc, PREVENT III, and ERICVA) or at 2 years (BASIL). The developed model is not without limitations, two of which are the single institution and the retrospective nature of the study. It is therefore believed that the fate of the ERICVA scale depends on its future multicentre and international implementation in order to obtain external Table 7 . Area under the curve of the different scales in the development and validation subsamples (*, p < 0.05).
Scales
Area validation that can make a more universally applicable model.
CONCLUSIONS
The developed ERICVA risk model has an acceptable predictive value of AFS 1 year after revascularization of CLI, and this capacity was slightly higher than the PREVENT III scale and clearly superior to the Finnvasc model in our clinical setting.
